Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer
Background: Glucagon-like peptide-1 (GLP-1) has crucial impact on glycemic control and weight loss physiologically. GLP-1 receptor agonists have been approved for treatment of diabetes and obesity. Emerging evidence suggests that GLP-1 receptor agonists exert anticancer effect in tumorigenesis and d...
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_bc9c7a2ce14845f18de60e100b64ee39 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Chaojun Zhu |e author |
700 | 1 | 0 | |a Yihong Lai |e author |
700 | 1 | 0 | |a Chengdong Liu |e author |
700 | 1 | 0 | |a Lan Teng |e author |
700 | 1 | 0 | |a Yuxin Zhu |e author |
700 | 1 | 0 | |a Xinyu Lin |e author |
700 | 1 | 0 | |a Xinyi Fu |e author |
700 | 1 | 0 | |a Qiuhua Lai |e author |
700 | 1 | 0 | |a Side Liu |e author |
700 | 1 | 0 | |a Side Liu |e author |
700 | 1 | 0 | |a Xiaohan Zhou |e author |
700 | 1 | 0 | |a Yuxin Fang |e author |
245 | 0 | 0 | |a Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer |
260 | |b Frontiers Media S.A., |c 2024-07-01T00:00:00Z. | ||
500 | |a 1663-9812 | ||
500 | |a 10.3389/fphar.2024.1387243 | ||
520 | |a Background: Glucagon-like peptide-1 (GLP-1) has crucial impact on glycemic control and weight loss physiologically. GLP-1 receptor agonists have been approved for treatment of diabetes and obesity. Emerging evidence suggests that GLP-1 receptor agonists exert anticancer effect in tumorigenesis and development. However, the role and mechanism of GLP-1 signaling-related genes in pan-cancer still need further study.Methods: We comprehensively investigated the aberrant expression and genetic alterations of GLP-1 signaling-related genes in 33 cancer types. Next, GLP-1 signaling score of each patient in The Cancer Genome Atlas were established by the single-sample gene set enrichment analysis. In addition, we explored the association of GLP-1 signaling score with prognostic significance and immune characteristics. Furthermore, qRT-PCR and immunohistochemistry staining were applied to verify the expression profiling of GLP-1 signaling-related genes in colorectal cancer (CRC) tissues. Wound-healing assays and migration assays were carried out to validate the role of GLP-1 receptor agonist in CRC cell lines.Results: The expression profiling of GLP-1 signaling-related genes is commonly altered in pan-cancer. The score was decreased in cancer tissues compared with normal tissues and the lower expression score was associated with worse survival in most of cancer types. Notably, GLP-1 signaling score was strongly correlated with immune cell infiltration, including T cells, neutrophils, dendritic cells and macrophages. In addition, GLP-1 signaling score exhibited close association with tumor mutation burden, microsatellite instability and immunotherapy response in patients with cancer. Moreover, we found that the expression of GLP-1 signaling-related genes ITPR1 and ADCY5 were significantly reduced in CRC tissues, and GLP-1 receptor agonist semaglutide impaired the migration capacity of CRC cells, indicating its protective role.Conclusion: This study provided a preliminary understanding of the GLP-1 signaling-related genes in pan-cancer, showing the prognosis significance and potential immunotherapeutic values in most cancer types, and verified the potential anticancer effect of GLP-1 receptor agonist in CRC. | ||
546 | |a EN | ||
690 | |a GLP-1 | ||
690 | |a pan-cancer | ||
690 | |a prognosis | ||
690 | |a immune infiltration | ||
690 | |a immunotherapy | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Frontiers in Pharmacology, Vol 15 (2024) | |
787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2024.1387243/full | |
787 | 0 | |n https://doaj.org/toc/1663-9812 | |
856 | 4 | 1 | |u https://doaj.org/article/bc9c7a2ce14845f18de60e100b64ee39 |z Connect to this object online. |